Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Two-Volt Josephson Arbitrary Waveform Synthesizer Using Wilkinson Dividers.

Flowers-Jacobs NE, Fox AE, Dresselhaus PD, Schwall RE, Benz SP.

IEEE Trans Appl Supercond. 2016 Sep;26(6). pii: 1400207. Epub 2016 Feb 19.

2.

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.

Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, Santell L, Zhang YW, Su Y, Kaufman DW, Billeci KL, Mai E, Moffat B, Lim A, Duenas ET, Phillips HS, Xiang H, Young JC, Vande Woude GF, Dennis MS, Reilly DE, Schwall RH, Starovasnik MA, Lazarus RA, Yansura DG.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. doi: 10.1073/pnas.1302725110. Epub 2013 Jul 23.

3.

Hepatocyte growth factor, a determinant of airspace homeostasis in the murine lung.

Calvi C, Podowski M, Lopez-Mercado A, Metzger S, Misono K, Malinina A, Dikeman D, Poonyagariyon H, Ynalvez L, Derakhshandeh R, Le A, Merchant M, Schwall R, Neptune ER.

PLoS Genet. 2013;9(2):e1003228. doi: 10.1371/journal.pgen.1003228. Epub 2013 Feb 14.

4.

Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, Lawrence D, Zheng Z, Koeppen H, Stern H, Schwall R, Ashkenazi A.

Clin Cancer Res. 2008 Dec 1;14(23):7733-40. doi: 10.1158/1078-0432.CCR-08-0670.

5.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX.

Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776.

6.

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival.

Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M.

Cancer Res. 2008 Jun 1;68(11):4360-8. doi: 10.1158/0008-5472.CAN-07-5960.

7.

Quantification of viable tumor microvascular characteristics by multispectral analysis.

Berry LR, Barck KH, Go MA, Ross J, Wu X, Williams SP, Gogineni A, Cole MJ, Van Bruggen N, Fuh G, Peale F, Ferrara N, Ross S, Schwall RH, Carano RA.

Magn Reson Med. 2008 Jul;60(1):64-72. doi: 10.1002/mrm.21470.

8.

Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent.

Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, Williams S, Cole MJ, Ross S, Schwall R.

Cancer Res. 2007 Jan 1;67(1):254-61.

9.

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.

Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52.

10.

Somatic mutations lead to an oncogenic deletion of met in lung cancer.

Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, Holcomb T, Pujara K, Stinson J, Fu L, Severin C, Rangell L, Schwall R, Amler L, Wickramasinghe D, Yauch R.

Cancer Res. 2006 Jan 1;66(1):283-9.

11.

Single photon source characterization with a superconducting single photon detector.

Hadfield RH, Stevens MJ, Gruber SS, Miller AJ, Schwall RE, Mirin RP, Nam SW.

Opt Express. 2005 Dec 26;13(26):10846-53.

PMID:
19503303
12.

Effect of anti-TGF-beta antibodies in syngeneic mouse models of metastasis.

Carano R, Li Y, Bao M, Li J, Berry L, Ross J, Kowalski J, French D, Dugger D, Schwall R, Wang Y, Fei D, Moseley SL, Filvaroff EH.

J Musculoskelet Neuronal Interact. 2004 Dec;4(4):377-8. No abstract available.

13.

The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure.

Jin H, Wyss JM, Yang R, Schwall R.

Curr Pharm Des. 2004;10(20):2525-33. Review.

PMID:
15320761
14.

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.

Cancer Res. 2004 Jul 15;64(14):4900-5.

15.

HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.

Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, Wong WL, Hollingshead P, Schwall R, Koeppen H, Erickson S.

Clin Cancer Res. 2004 Apr 1;10(7):2499-511.

16.

Quantification of tumor tissue populations by multispectral analysis.

Carano RA, Ross AL, Ross J, Williams SP, Koeppen H, Schwall RH, Van Bruggen N.

Magn Reson Med. 2004 Mar;51(3):542-51.

17.

Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met.

Nguyen TH, Loux N, Dagher I, Vons C, Carey K, Briand P, Hadchouel M, Franco D, Jouanneau J, Schwall R, Weber A.

Cancer Gene Ther. 2003 Nov;10(11):840-9.

PMID:
14605670
18.

Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to hepatocyte growth factor.

Zlot C, Ingle G, Hongo J, Yang S, Sheng Z, Schwall R, Paoni N, Wang F, Peale FV Jr, Gerritsen ME.

J Biol Chem. 2003 Nov 28;278(48):47654-9. Epub 2003 Sep 17.

19.

Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth.

Mendoza N, Fong S, Marsters J, Koeppen H, Schwall R, Wickramasinghe D.

Cancer Res. 2003 Mar 1;63(5):1020-4.

20.

Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction.

Jin H, Yang R, Li W, Ogasawara AK, Schwall R, Eberhard DA, Zheng Z, Kahn D, Paoni NF.

J Pharmacol Exp Ther. 2003 Feb;304(2):654-60.

PMID:
12538818
21.

Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.

Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D.

Cancer Res. 2002 Oct 1;62(19):5485-8.

22.

Efficient gene transduction to cultured hepatocytes by HIV-1 derived lentiviral vector.

Ohashi K, Park F, Schwall R, Kay M.

Transplant Proc. 2002 Aug;34(5):1431-3. No abstract available.

PMID:
12176427
23.

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A.

Nat Med. 2002 Mar;8(3):274-81.

PMID:
11875499
24.

Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling.

Tice DA, Szeto W, Soloviev I, Rubinfeld B, Fong SE, Dugger DL, Winer J, Williams PM, Wieand D, Smith V, Schwall RH, Pennica D, Polakis P.

J Biol Chem. 2002 Apr 19;277(16):14329-35. Epub 2002 Feb 6.

25.

Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling.

Rubin JS, Day RM, Breckenridge D, Atabey N, Taylor WG, Stahl SJ, Wingfield PT, Kaufman JD, Schwall R, Bottaro DP.

J Biol Chem. 2001 Aug 31;276(35):32977-83. Epub 2001 Jul 2.

26.

Overexpression of the retinoic acid-responsive gene Stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid.

Szeto W, Jiang W, Tice DA, Rubinfeld B, Hollingshead PG, Fong SE, Dugger DL, Pham T, Yansura DG, Wong TA, Grimaldi JC, Corpuz RT, Singh JS, Frantz GD, Devaux B, Crowley CW, Schwall RH, Eberhard DA, Rastelli L, Polakis P, Pennica D.

Cancer Res. 2001 May 15;61(10):4197-205.

27.

cMet activation allows persistent engraftment of ectopically transplanted xenogenic human hepatocytes in mice.

Ohashi K, Meuse L, Schwall R, Kay MA.

Transplant Proc. 2001 Feb-Mar;33(1-2):587-8. No abstract available.

PMID:
11266970
28.

Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.

Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, Schwall R, Ferrara N, Gerritsen ME.

Am J Pathol. 2001 Mar;158(3):1111-20.

29.

Hepatocyte growth factor receptor in acute tubular necrosis.

Rabkin R, Fervenza F, Tsao T, Sibley R, Friedlaender M, Hsu F, Lassman C, Hausmann M, Huie P, Schwall RH.

J Am Soc Nephrol. 2001 Mar;12(3):531-40.

30.

Engraftment of autologous retrovirally transduced hepatocytes after intraportal transplantation into nonhuman primates: implication for ex vivo gene therapy.

Andreoletti M, Loux N, Vons C, Nguyen TH, Lorand I, Mahieu D, Simon L, Di Rico V, Vingert B, Chapman J, Briand P, Schwall R, Hamza J, Capron F, Bargy F, Franco D, Weber A.

Hum Gene Ther. 2001 Jan 20;12(2):169-79.

PMID:
11177554
31.

[Treatment of intra-articular calcaneus fractures with a para-articular external fixator]].

Schwall R, Junge RH, Zenker W, Besch L.

Unfallchirurg. 2000 Dec;103(12):1065-72. German.

PMID:
11148902
32.

Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines.

Qadan LR, Perez-Stable CM, Schwall RH, Burnstein KL, Ostenson RC, Howard GA, Roos BA.

Endocrinology. 2000 Jul;141(7):2567-73.

PMID:
10875259
33.

Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses.

Ohashi K, Marion PL, Nakai H, Meuse L, Cullen JM, Bordier BB, Schwall R, Greenberg HB, Glenn JS, Kay MA.

Nat Med. 2000 Mar;6(3):327-31.

PMID:
10700236
34.

Safety and antitumor activity of recombinant soluble Apo2 ligand.

Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH.

J Clin Invest. 1999 Jul;104(2):155-62.

35.

Hepatocyte growth factor induces hepatocyte proliferation in vivo and allows for efficient retroviral-mediated gene transfer in mice.

Patijn GA, Lieber A, Schowalter DB, Schwall R, Kay MA.

Hepatology. 1998 Sep;28(3):707-16.

PMID:
9731563
36.

Retrovirus-mediated in vivo gene transfer in the replicating liver using recombinant hepatocyte growth factor without liver injury or partial hepatectomy.

Kosai KI, Finegold MJ, Thi-Huynh BT, Tewson M, Ou CN, Bowles N, Woo SL, Schwall RH, Darlington GJ.

Hum Gene Ther. 1998 Jun 10;9(9):1293-301.

PMID:
9650614
37.

Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.

Yi S, Chen JR, Viallet J, Schwall RH, Nakamura T, Tsao MS.

Br J Cancer. 1998 Jun;77(12):2162-70.

38.

Lacrimal gland growth factors and receptors: lacrimal fibroblastic cells are a source of tear HGF.

Wilson SE, Li Q, Mohan RR, Tervo T, Vesaluoma M, Bennett GL, Schwall R, Tabor K, Kim J, Hargrave S, Cuevas KH.

Adv Exp Med Biol. 1998;438:625-8. Review. No abstract available.

PMID:
9634946
39.

Vascular endothelial growth factor is essential for corpus luteum angiogenesis.

Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH.

Nat Med. 1998 Mar;4(3):336-40.

PMID:
9500609
40.
41.

Hemodynamic effects of scatter factor in conscious rats.

Yang R, Bunting S, Ko A, Schwall R, Jin H.

J Cardiovasc Pharmacol. 1997 Sep;30(3):294-301.

PMID:
9300311
42.

Expression of interleukin-1beta in human breast carcinoma.

Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, Turkel G, Polverini PJ, Goldberg ID, Rosen EM.

Cancer. 1997 Aug 1;80(3):421-34.

PMID:
9241076
43.

Tear hepatocyte growth factor (HGF) availability increases markedly after excimer laser surface ablation.

Tervo T, Vesaluoma M, Bennett GL, Schwall R, Helena M, Liang Q, Wilson SE.

Exp Eye Res. 1997 Apr;64(4):501-4.

PMID:
9227267
44.
45.

Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2.

Schwall RH, Chang LY, Godowski PJ, Kahn DW, Hillan KJ, Bauer KD, Zioncheck TF.

J Cell Biol. 1996 May;133(3):709-18.

46.

Hepatocyte growth factor and hepatocyte growth factor receptor in the lacrimal gland, tears, and cornea.

Li Q, Weng J, Mohan RR, Bennett GL, Schwall R, Wang ZF, Tabor K, Kim J, Hargrave S, Cuevas KH, Wilson SE.

Invest Ophthalmol Vis Sci. 1996 Apr;37(5):727-39.

PMID:
8603858
47.

Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma.

Rahimi N, Tremblay E, McAdam L, Park M, Schwall R, Elliott B.

Cell Growth Differ. 1996 Feb;7(2):263-70.

48.

Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity.

Zioncheck TF, Richardson L, Liu J, Chang L, King KL, Bennett GL, Fügedi P, Chamow SM, Schwall RH, Stack RJ.

J Biol Chem. 1995 Jul 14;270(28):16871-8.

49.

Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor.

Roos F, Ryan AM, Chamow SM, Bennett GL, Schwall RH.

Am J Physiol. 1995 Feb;268(2 Pt 1):G380-6.

PMID:
7864135
50.

Induction of apoptosis in the murine liver with recombinant human activin A.

Hully JR, Chang L, Schwall RH, Widmer HR, Terrell TG, Gillett NA.

Hepatology. 1994 Oct;20(4 Pt 1):854-62.

PMID:
7927226

Supplemental Content

Loading ...
Support Center